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Targeted Drug Delivery Systems
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Abstract—The development of a 3-dimensional (3-D) navigation
system of ferromagnetic particles in a flow system was performed.
In order to improve the practice of using externally-applied mag-
netic fields for targeting the magnetic particles to a circumscribed
body region, we tested the feasibility of a novel 3-D navigation
system, made by applying a strong external (magnetic) field
through a GdBaCuO bulk superconductor. A 3-D theoretical
model is proposed and used in order to evaluate the efficiency of
the navigation/retention of magnetic particles in the flow system.
Furthermore, an experimental model system was made and the
efficiency of a prototype system was examined. Comparisons of
experimental and the corresponding calculation results were made
to examine the theoretical model system.
Index Terms—Bulk superconductor, drug delivery system, fer-
romagnetic particle, magnetic targeting.
I. INTRODUCTION
THE concept of magnetically targeted drug delivery systems(MT-DDS) shows considerable potential for a wide va-
riety of medical applications that include, among others, cancer
therapy, blood detoxification, anti-ischemic therapeutics, and
drugs to prevent programmed cell death. However, there are
several problems associated with the use of external magnets in
magnetic drug targeting [1]. One limitation results from the neg-
ative influence that high blood flow velocities in large arteries
or veins may have on the accumulation of medicative magnetic
micro/nano-particles at the target site. Another problem is the
depth of the target site. Sites which are more than 2 cm deep
in the human body are difficult to target because the strength
of the magnetic field decreases abruptly with distance. Unfor-
tunately, the use of larger magnets to extend the magnetic field
to inner parts of the body may not resolve the problem since
low magnetic field gradients tend to result. The magnetic force
is strongly dependent on the gradient of the magnetic field and
thus the ability to retain magnetic micro/nano-particles by larger
magnets becomes reduced. It is for this very reason that we pro-
pose the application of an external superconducting magnet.
So far, we have developed an integrated system based on fer-
romagnetic, nonvirus vector attached to a nano-sized maghemite
particle as a tool of targeted but noninvasive delivery of drugs
for gene therapy within the human vasculature. Indeed, we found
that a magnetically assisted gene transfection system has consid-
erable potential for a gene therapy [2]. Drug targeting is achieved
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through venous injection of drug-loaded magnetic, biocompat-
ible micro/nano-particles which freely circulate throughout the
body but are magnetically trapped and concentrated at the local
site under magnetic field (targeted delivery). Our system offers
the following advantages over the use of other externally-applied
magneticfieldsystems:1)enablingrelativelyhigh localmagnetic
gradients deep within the human body; 2) permitting multiple,
targeted drug delivery and hence treatment modalities utilizing
convenient systemic drug injections (i.e., repeated targeted drug
delivery in cancer therapy).
Theoretical studies have proven the efficiency of this novel
magnetically targeted drug delivery system where the strong
magnet can collect magnetic micro/nano-particles from arterial/
venous blood flow [2]. In the present paper, an in vitro flow
model system was developed to validate the theoretical model
and evaluate the efficiency of a bulk superconducting magnet
to accumulate ferromagnetic particles (2 diameter) inside
blood flow.
II. CALCULATION METHOD
A 2-D schematic of the controlling particle system used for
modeling the magnetically targeting of magnetic particles in the
flow system is shown in Fig. 1. The particle feels a viscous
drag force when it begins to move. Simultaneously, the mag-
netic force acts floating ferromagnetic particles.
The parameters used for calculating the particle trajectory are
summarized in Table I. The black and white color in the flow
system represents a measure of the flow velocity. The flow ve-
locity is high at the center, and low near the inner surfaces of
the flow system. The velocity distribution of the flow system
was calculated using ANSYS 9.0 (Fig. 2).
The trajectory of the magnetic particles is calculated ac-
cording to the following model.
The trajectory of the magnetic particles is calculated ac-
cording to the following model. When the magnetic particle
is assumed to be spherical, the energy arising from
magnetic force is represented by the following:
(1)
When velocity of the magnetic particle is different from the
flow velocity , the particle is dragged by the fluid and the drag
force can be expressed using Stokes’s law as
(2)
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Fig. 1. Schematic of the controlling particle system utilized for modeling the
targeting of magnetic particle inside the flow system under the magnetic force.
The trajectory of the magnetic particles from the initial position (X ;Y ) to
the final position (X ;Y ) under the magnetic field was calculated using
ANSYS9.0.
Therefore, the equation to represent the particle motion is
(3)
Substituting (1) and (2) into (3)
(4)
and solving, we obtain
(5)
where is a constant of integration. Thus, the displacement,
can be written as
(6)
Where is a constant of integration.
To obtain and , we calculate and at two different
times and use and calculated through
ANSYS 9.0.
(7)
(8)
Substituting (7) and (8) into (5) and (6), we obtained and
at . When we calculate the integrated constant,
and at are taken from the analyzed data using
ANSYS 9.0 for magnetic field and flow system, respectively.
Fig. 2. Calculated magnetic flux density using ANSYS 9.0 induced by the
magnet placed outside the flow system. The Y-shape tube is the model flow
system, and the right side of the figure shows the strength of the magnetic flux
density (white color represents strong and black color weak). The left side shows
the mesh sizes of the calculation.
TABLE I
CALCULATION PARAMETERS
III. CALCULATION RESULT
The calculated particle trajectory is shown in Fig. 3. In Fig.
3(c), the accumulated particles are seen at the right-below wall
of the flow system. This result indicates the feasibility of the
magnetically targeted drug delivery system. The simulation re-
sults also show the efficiency of the accumulation of the mag-
netic particles at the target site (final position). In the simula-
tion without the magnet (Fig. 3(b)), 53\% of the particles go
into upper tube after branch point and the rest (47\%) go into
the lower tube. This result shows that the particle accumulation
does not occur. On the other hand, in the case of simulation with
the magnet (Fig. 3(c)), the number of the accumulated particles
in the lower tube after the branch point was 2.7 times higher
than that of those going to upper tube. But, 27\% of the number
of the particles was captured before branch point thanks to the
shape of the induced magnetic field. The obtained results clearly
show that the magnetic accumulation in the flow system was
possible even in the case where magnet was placed outside the
flow system.
IV. EXPERIMENT
A. Magnet
A photograph of the bulk type of superconducting magnet
system used in this experiment was shown in Fig. 4. The magnet
was a GdBaCuO bulk superconductor (Nippon Steel, Japan) of
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Fig. 3. Calculated particle trajectory under flow system (flow velocity: 200
mm/s). Bold points represent magnetic particles under magnetic field. (a): Ini-
tial position (Time = 0 sec), (b) final position without magnet (Time =
0:42 sec), and (c) final position with magnet which was placed in the place
under 35 mm from outside the flow system (Time = 0:42 sec).
cylindrical shape (45 mm large and 15 mm thick). Magnetiza-
tion was performed by the pulse magnetization method (PFM)
that can be done with copper wire [3]. The bulk superconductor
can generate a strong magnetic field in an open space. Therefore,
the magnetic field generated by bulk superconducting magnet
is wide range and feasible to MT-DDS. Fig. 5 shows the mag-
netic flux density of a vertical element of the magnet against the
distance from the surface of the cover. The calculated value of
magnetic flux density with the distance shows good agreement
with the measured values (Fig. 5). This suggests that the result
of the magnetic field analysis by the finite element method is
correct and can allow us to design the magnetic field and the
magnet itself.
B. Experimental Model System
An experimental model system is shown in Fig. 6. The
branching tube was placed at the same distance in the case of a
rat where the vena cava was assumed to be located at 50 mm
from the body surface of a rat. The size of the model system
was , made of acrylic box. The
diameter of the tube was 2 mm and the length was 100 mm.
Fig. 4. Photograph of the bulk superconducting magnet.
Fig. 5. Calculated and experimentally determined magnetic flux density of a
vertical element of the magnet against the distance from the surface of the cover
above the bulk magnet.
Fig. 6. Schematic of experimental model system for magnetic targeting.
The center of the tube in the flow direction has a branch with
an angle of 60 degrees.
Fig. 7 shows the result of the experimentally accumulating
test using a glass tube. Ferromagnetic particles flow from the
left side (corresponding to the initial position in Fig. 1) and feel
the drag force and the magnetic force. It is clearly seen that the
ferromagnetic particles are accumulated in a local part of the
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Fig. 7. Results of the experimentally accumulating test using the tube.
glass tube by the magnetic force. These ferromagnetic particles
have a diameter of 2 and a magnetic susceptibility of 68
emu/g. This experimental result shows that particles are accu-
mulated, as predicted (see Fig. 3(c)) even at a flow velocity of
200 mm/s.
V. CONCLUSION
This theoretical and experimental study shows the feasibility
of a novel magnetically targeted drug delivery system, where
a strong magnet can accumulate magnetic micro/nano-particles
in the flow system. In the present paper, an in vitro flow model
system was established to examine the theoretical model and
evaluate the efficiency of bulk superconducting magnet to ac-
cumulate of ferromagnetic particle, 2 diameter, inside flow
system using an externally placed magnet at the distance of
35mm from the flow system. In vitro flow experiments were
used to check the accuracy of the theoretical model of a strong
magnet for accumulating magnetic particle under flow system.
Comparisons of experimental and corresponding modeling data
verified theoretical predictions. A further study using a bulk su-
perconducting magnet confirmed the efficiency of accumulating
particles even at flow velocities of 200 mm/s. The obtained re-
sults show that the magnetic accumulation in the flow system
was possible even in the case where magnet was placed at the
distance of 35 mm from the flow system.
Two important findings were obtained from this study. The
first is that our 2-D computational approach is sufficient to ex-
amine the relatively simple magnetic system, as we see good
correlation between model and experiment. Secondly, the cap-
ture efficiencies are sufficiently enhanced with the placement
of the bulk superconducting magnet to warrant further investi-
gation into the clinical efficacy of this magnetic drug targeting
system.
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